FIELD: medicine.
SUBSTANCE: set of inventions relates to medicine, in particular to the use of regulator of neutrophil activation. Use of a regulator of neutrophil activation including batroxobin as an active ingredient: to inhibit neutrophil degranulation, to inhibit Mac-1 expression by neutrophils, to inhibit the formation of NETs by neutrophils, to inhibit the transendothelial migration of neutrophils as well as to treat diseases caused by activation of neutrophils which are selected from a group consisting of sepsis, acute respiratory distress syndrome, acute pancreatitis and acute lung disorder.
EFFECT: said solution enables regulating neutrophil activation for suppressing inflammatory reaction.
5 cl, 6 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT FOR TREATING LOWER URINARY TRACT DISEASE AND AGENT FOR IMPROVING LOWER URINARY TRACT SYMPTOM | 2009 |
|
RU2527679C2 |
| MEDICATION FOR REDUCTION OF SIDE EFFECT OF ANTI-CANCER DRUG | 2008 |
|
RU2469740C2 |
| METHOD OF CONTROLLING NEUTROPHIL ACTIVATION IN IN VITRO MODEL | 2019 |
|
RU2716492C1 |
| METHOD FOR UTILIZATION OF FIBRIN SEALING MATERIAL, METHOD OF PREPARING COMPOSITION, COMPOSITIONS, AND KITS | 1993 |
|
RU2143924C1 |
| PREPARATION INHIBITING MALIGNANT TUMOUR DEVELOPMENT AND CONTAINING DIS-A-FIBRIN | 2005 |
|
RU2358754C2 |
| METHOD FOR SUPPRESSING EXCESSIVE NEUTROPHIL ACTIVATION IN AN EX VIVO MODEL | 2022 |
|
RU2794568C1 |
| PREPARATION CONTAINING BATROXOBIN, FOR INHIBITION OF LOCAL INVASION OF MALIGNANT TUMOURS | 2005 |
|
RU2362582C2 |
| METHOD FOR THROMBIN AND FIBRINOGEN ACTIVITY AND FUNCTIONALITY TEST | 2008 |
|
RU2462721C2 |
| FIBRINOGEN CONTENT ANALYSIS | 2012 |
|
RU2619256C2 |
| METHOD FOR DETERMINATION OF FUNCTIONAL FIBRINOGEN | 2017 |
|
RU2669796C1 |
